LIFSCREEN : Evaluation of Whole Body MRI for Early Detection of Cancers in Subjects With P53 Mutation (Li-Fraumeni Syndrome)
Trial Sites
Back to Top
Basic Trial Information
Trial Description
Summary
Eligibility Criteria
Trial Contact Information
| Phase | Type | Status | Age | Sponsor | Protocol IDs |
|---|---|---|---|---|---|
| Phase III | Screening | Active | 5 to 71 | Other | CSET2011/1748 NCT01464086 |
Summary
The purpose of this study is to compare the diagnostic efficacy of two follow-up schedules for the early detection of cancers in the population under study on cancer incidence at 3 years.
Eligibility Criteria
Inclusion Criteria:
- P53 mutation
Trial Lead Organizations/Sponsors
Institut Gustave Roussy
| Olivier caron |  | Ph: 33 1 42 11 51 78 |
| Email: olivier.caron@igr.fr | ||
Trial Sites
|
|
|
|
| France | |||
|
|||
| Villejuif | |||
|
|||
| Institut Gustave Roussy | |||
| Olivier caron | Ph: 33 1 42 11 51 78 | ||
Link to the current ClinicalTrials.gov record.
NLM Identifer NCT01464086
Information obtained from ClinicalTrials.gov on December 14, 2011
Note: Information about this trial is from the ClinicalTrials.gov database. The versions designated for health professionals and patients contain
the same text. Minor
changes may be made to the ClinicalTrials.gov record to standardize the names of study sponsors, sites, and
contacts. Cancer.gov only lists sites that are recruiting patients for active trials, whereas ClinicalTrials.gov lists all sites for all trials. Questions and comments regarding the presented information should
be directed to ClinicalTrials.gov.
Back to Top
